Why Did Biodesix Stock Fall 26% Today?

  • Biodesix Inc's BDSX second-quarter revenues grew 183% Y/Y to $11.9 million, but short of the $21.14 million consensus.
  • COVID-19 testing revenues grew to $6.1 million from $1.4 million in Q2 2020, while lung diagnostic revenues rose to $4.8 million from $2.3 million, and biopharma revenues increased to $1.0 million from $596,000 a year ago.
  • In Q1 FY21, Biodesix recorded $23.2 million in COVID-19 testing revenue, and it noted that the sequential decline was consistent with its prior expectations as COVID-19 vaccinations accelerated in Q2.
  • Meanwhile, the firm said that lung testing revenues continued to recover due to the uptake in COVID-19 vaccinations. It added that growth in this segment was led by its blood-based Nodify XL2 and Nodify CDT tests.
  • Further, the launch of its 72-hour blood-based, liquid biopsy next-generation sequencing test is expected in Q1 2022, supplementing Biodesix's VeriStrat and GeneStrat proteomic tests, which can return results in 36 hours.
  • Biodesix had an EPS loss of $(0.41) compared to $(30.06) a year ago. The consensus Wall Street estimate was for a loss of $(0.29).
  • The firm's R&D spending rose 57% to $3.3 million, while its sales, marketing, general, and administrative costs grew 68% to $11.4 million.
  • Biodesix exited the quarter with $56.3 million in cash and cash equivalents.
  • Price Action: BDSX shares closed down 26.30% at $7.25 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsShort IdeasHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!